Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871607 · ClinicalTrials.gov registry record · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
A Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04871607: Recruiting Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
NCT04871607 is a Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 33 participants, below the 39-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04871607, a Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.
Primary Outcome
Disease relapse or progression, or death from any cause, whichever occurs first. Will be calculated using the Kaplan-Meier method.
Conditions Studied
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- BIOLOGICAL Basiliximab
- BIOLOGICAL Genetically Engineered Hematopoietic Stem Progenitor Cells
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2029-10-02 |
| Phase | Phase 2 |
What NCT04871607 shows while recruiting
NCT04871607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 39-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (15% lower).
The record links to 2 conditions, with Refractory Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Etoposide is the first listed.
NCT04871607 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04871607 about?
NCT04871607 is a clinical study titled "Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma". This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibo...
What is the current status of trial NCT04871607?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2021-11-02. Estimated completion is 2029-10-02.
What conditions does trial NCT04871607 study?
This clinical trial studies the following conditions: Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma.
What interventions are being tested in trial NCT04871607?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), Basiliximab (BIOLOGICAL), Genetically Engineered Hematopoietic Stem Progenitor Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04871607?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871607 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04871607's enrollment target sits among peer trials
33 6th of 11 higher than 6 of 11 other Refractory Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
- NCT05225363 · 33 participants · Phase 1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI